Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages 436-443

  Lock, Johan F ^a   Malinowski, Maciej ^a   Schwabauer, Eugen ^a   Martus, Peter ^a   Pratschke, Johann ^a   Seehofer, Daniel ^a   Puhl, Gero ^a   Neuhaus, Peter ^a   Stockmann, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Graft dysfunction; Graft failure; LiMAx test; Liver function; Methacetin

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; DELIRIUM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; HUMAN; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMAL LIVER FUNCTION CAPACITY; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SEIZURE; SENSITIVITY AND SPECIFICITY;

FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TACROLIMUS; TISSUE DISTRIBUTION; TISSUE DONORS;

EID: 79958708777     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01264.x     Document Type: Article

References (27)

1. Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004: 77: S44.
2. Sevmis S, Karakayali H, Emiroglu R, Akkoc H, Haberal M. Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc 2007: 39: 1211.
3. Hedayat S, Kershner RP, Su G. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. J Biopharm Stat 1996: 6: 411.
4. Mor E, Yussim A, Chodoff L, Schwartz ME. New immunosuppressive agents for maintenance therapy in organ transplantation. BioDrugs 1997: 8: 469.
5. Venkataramanan R, Shaw LM, Sarkozi L et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001: 41: 542.
6. Dimartini A, Fontes P, Dew MA, Lotrich FE, De Vera M. Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity. Liver Transpl 2008: 14: 815.
7. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992: 20: 753.
8. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005: 6: 37.
9. Goto M, Masuda S, Kiuchi T et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004: 14: 471.
10. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004: 43: 623.
11. Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 2004: 42: 1204.
12. Boillot O, Mayer DA, Boudjema K et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005: 11: 61.
13. Stockmann M, Lock JF, Riecke B et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009: 250: 119.
14. Lock JF, Schwabauer E, Martus P et al. Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl 2010: 16: 172.
15. Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003: 326: 41.
16. Stockmann M, Lock JF, Malinowski M et al. The LiMAx test - A new liver function test for prediction of postoperative outcome in liver surgery. HPB (Oxford) 2010: 12: 139.
17. Jorgensen KA, Povlsen JV, Poulsen JH. Optimal time for determination of blood tacrolimus level. Transplant Proc 2001: 33: 3164.
18. Macfarlane GD, Shaw LM, Venkataramanan R et al. Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function. Ther Drug Monit 1999: 21: 585.
19. Sugawara Y, Makuuchi M, Kaneko J et al. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002: 16: 102.
20. Abu-Elmagd K, Fung JJ, Alessiani M et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991: 52: 71.
21. Abu-Elmagd KM, Fung JJ, Alessiani M et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc 1991: 23: 2771.
22. Parker BM, Cywinski JB, Alster JM et al. Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl 2008: 14: 46.
23. Schmidt LE, Olsen AK, Stentoft K et al. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. Clin Pharmacol Ther 2001: 70: 446.
24. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991: 256: 1189.
25. Lown K, Kolars J, Turgeon K et al. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992: 51: 229.
26. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005: 97: 125.
27. Cozza KL, Armstrong SC, Oesterheld JR. Drug Interaction Principles for Medical Practice - Cytochrome P450s. 2nd edn: Arlington, VA: American Psychiatric Publishing Inc.; 2003.